Abstract | INTRODUCTION: People with mental retardation often display aggressive behavior against themselves or others making care within institutions or foster families difficult. Due to a lack of viable alternatives, antipsychotics of the first and second generations are often used for long-term treatment despite the fact that only data about short-term treatment exist. METHODS: A short-time withdrawal trial of 12 weeks (n = 39) was extended at open label to 2 years. 31 patients received zuclopenthixol after the end of the withdrawal and were examined using the same instruments as in the withdrawal period ( DAS, MOAS, CGI). RESULTS: Patients still treated with zuclopenthixol after 2 years (n = 21) benefitted, compared to the drop-outs (n = 10). Analyses of time trends revealed an early effect of zuclopenthixol which could not be enhanced afterwards. DISCUSSION:
|
Authors | F Hässler, T Glaser, O Reis |
Journal | Pharmacopsychiatry
(Pharmacopsychiatry)
Vol. 44
Issue 7
Pg. 339-43
(Nov 2011)
ISSN: 1439-0795 [Electronic] Germany |
PMID | 21993867
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © Georg Thieme Verlag KG Stuttgart · New York. |
Chemical References |
- Antipsychotic Agents
- Clopenthixol
|
Topics |
- Adult
- Aggression
(psychology)
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Attention Deficit and Disruptive Behavior Disorders
(drug therapy, psychology)
- Clopenthixol
(administration & dosage, adverse effects, therapeutic use)
- Double-Blind Method
- Endpoint Determination
- Female
- Follow-Up Studies
- Humans
- Intellectual Disability
(psychology)
- Male
- Middle Aged
- Prospective Studies
- Treatment Outcome
- Young Adult
|